<DOC>
	<DOC>NCT02629757</DOC>
	<brief_summary>This study is being conducted to help determine whether β-elemene as maintain treatment for complete remission patients of newly diagnosed malignant gliomas following standard treatment, is able to delay tumor growth, or impact how long people with newly diagnosed high-grade glioma.</brief_summary>
	<brief_title>A Study on β-elemene as Maintain Treatment for Complete Remission Patients of Newly Diagnosed Malignant Gliomas Following Standard Treatment</brief_title>
	<detailed_description>This study is being conducted to help determine whether β-elemene as maintain treatment for complete remission patients of newly diagnosed malignant gliomas following standard treatment, is able to delay tumor growth, or impact how long people with newly diagnosed high-grade glioma. β-elemene will be given 600mg/d,d1-14,q28 days for 6 cycles.</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<criteria>Page 3 of 4 [DRAFT] Arms Assigned Interventions Temodar Experimental: temozolomide +αIFN Four weeks after radiotherapy, patients will be received 6 cycle of temozolomide plus αIFN αIFN： 3mIU (3million) Day1,3,5 of each 28 day TMZ：150 mg/m^2 daily on Days 26 of each 28 day study cycle and 200 mg/m^2 daily of subsequent cycles Drug: Temozolomide dosed at 200 mg/m2 (150 mg/m2 for the first cycle) daily for 5 consecutive days, repeated every 28 days Other Names: • Temodar Drug: αIFN 3mIU (3million) D1，3，5 Other Names: • INTRONA Outcome Measures Primary Outcome Measure: 1. Overall survival [Time Frame: 5year] [Safety Issue: No] Secondary Outcome Measure: 2. Quality of life [Time Frame: 5year] [Safety Issue: No] Eligibility Minimum Age: 18 Years Maximum Age: 75 Years Gender: Both Accepts Healthy Volunteers?: No Criteria: Age: 18 years to 75 years complete remission patients of newly diagnosed WHO IIIIV glioma following standard treatment Karnofsky Performance Score ≥ 60 Adequate bone marrow, liver and renal function Ability of subject to understand character and individual consequences of the clinical trial Written informed consent anticipating survival ≥2 months Refusal to participate the study Known hypersensitivity or contraindication to temozolomide Incompletely radiation Pregnant or lactating females Malignant tumor other than brain tumor Contraindicated for MRI examination Unable to comply with the followup studies of this trial Purulent and chronic infected wounds Uncontrolled psychotic disorders or epilepsy progression disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>High-grade glioma</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>β-elemene</keyword>
</DOC>